A Role of Variance in Interferon Genes to Disease Severity in COVID-19 Patients

被引：9

作者：

Gozman, Leonid ^{[1
]}

Perry, Kellie ^{[2
]}

Nikogosov, Dimitri ^{[3
]}

Klabukov, Ilya ^{[4
]}

Shevlyakov, Artem ^{[3
]}

Baranova, Ancha ^{[2
,3
,5
]}

机构：

[1] Tel Aviv Univ, Sackler Sch Med, Ramat Aviv, Israel

[2] George Mason Univ, Sch Syst Biol, Fairfax, VA 22030 USA

[3] Atlas Biomed Grp Ltd, London, England

[4] Minist Hlth Russian Federat, Dept Regenerat Technol & Biofabricat, Natl Med Res Radiol Ctr, Obninsk, Russia

[5] Res Ctr Med Genet, Moscow, Russia

来源：

FRONTIERS IN GENETICS | 2021年 / 12卷

关键词：

COVID-19; interferons; SARS-CoV-2; signaling; type I interferon; differential activity; ABO BLOOD-GROUP; HEPATITIS-C; IFN-LAMBDA; SPONTANEOUS CLEARANCE; WIDE ASSOCIATION; STIMULATED GENES; VIRUS-INFECTION; HIV CONTROL; IL28B; POLYMORPHISMS;

D O I：

10.3389/fgene.2021.709388

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

The rapid rise and global consequences of the novel coronavirus disease 19 (COVID-19) have again brought the focus of the scientific community on the possible host factors involved in patient response and outcome to exposure to the virus. The disease severity remains highly unpredictable, and individuals with none of the aforementioned risk factors may still develop severe COVID-19. It was shown that genotype-related factors like an ABO Blood Group affect COVID-19 severity, and the risk of infection with SARS-CoV-2 was higher for patients with blood type A and lower for patients with blood type O. Currently it is not clear which specific genes are associated with COVID-19 severity. The comparative analysis of COVID-19 and other viral infections allows us to predict that the variants within the interferon pathway genes may serve as markers of the magnitude of immune response to specific pathogens. In particular, various members of Class III interferons (lambda) are reviewed in detail.

引用

页数：10

共 116 条

[41] Inhibition of the interaction between the SARS-CoV Spike protein and its cellular receptor by anti-histo-blood group antibodies [J].

Guillon, Patrice ;

Clement, Monique ;

Sebille, Veronique ;

Rivain, Jean-Gerard ;

Chou, Chih-Fong ;

Ruvoen-Clouet, Nathalie ;

Le Pendu, Jacques .

GLYCOBIOLOGY, 2008, 18 (12) :1085-1093

[42] Efficacy of convalescent plasma according to blood groups in COVID-19 patients [J].

Hacibekiroglu, Tuba ;

Kalpakci, Yasin ;

Genc, Ahmet Cihat ;

Hacibekiroglu, Ilhan ;

Sunu, Cenk ;

Saricaoglu, Adem ;

Tomak, Yakuo ;

Karabay, Oguz ;

Koroglu, Mehmet .

TURKISH JOURNAL OF MEDICAL SCIENCES, 2021, 51 (01) :45-48

[43] Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients [J].

Hadjadj, Jerome ;

Yatim, Nader ;

Barnabei, Laura ;

Corneau, Aurelien ;

Boussier, Jeremy ;

Smith, Nikaia ;

Pere, Helene ;

Charbit, Bruno ;

Bondet, Vincent ;

Chenevier-Gobeaux, Camille ;

Breillat, Paul ;

Carlier, Nicolas ;

Gauzit, Remy ;

Morbieu, Caroline ;

Pene, Frederic ;

Marin, Nathalie ;

Roche, Nicolas ;

Szwebel, Tali-Anne ;

Merkling, Sarah H. ;

Treluyer, Jean-Marc ;

Veyer, David ;

Mouthon, Luc ;

Blanc, Catherine ;

Tharaux, Pierre-Louis ;

Rozenberg, Flore ;

Fischer, Alain ;

Duffy, Darragh ;

Rieux-Laucat, Frederic ;

Kerneis, Solen ;

Terrier, Benjamin .

SCIENCE, 2020, 369 (6504) :718-+

[44] Interferon lambda 4 signals via the IFNλ receptor to regulate antiviral activity against HCV and coronaviruses [J].

Hamming, Ole J. ;

Terczynska-Dyla, Ewa ;

Vieyres, Gabrielle ;

Dijkman, Ronald ;

Jorgensen, Sanne E. ;

Akhtar, Hashaam ;

Siupka, Piotr ;

Pietschmann, Thomas ;

Thiel, Volker ;

Hartmann, Rune .

EMBO JOURNAL, 2013, 32 (23) :3055-3065

[45] Direct Effects of Type I Interferons on Cells of the Immune System [J].

Hervas-Stubbs, Sandra ;

Luis Perez-Gracia, Jose ;

Rouzaut, Ana ;

Sanmamed, Miguel F. ;

Le Bon, Agnes ;

Melero, Ignacio .

CLINICAL CANCER RESEARCH, 2011, 17 (09) :2619-2627

[46]

Hoffmann Markus, 2020, bioRxiv, DOI 10.1101/2020.08.05.237651

[47] The association of ABO blood group with indices of disease severity and multiorgan dysfunction in COVID-19 [J].

Hoiland, Ryan L. ;

Fergusson, Nicholas A. ;

Mitra, Anish R. ;

Griesdale, Donald E. G. ;

Devine, Dana, V ;

Stukas, Sophie ;

Cooper, Jennifer ;

Thiara, Sonny ;

Foster, Denise ;

Chen, Luke Y. C. ;

Lee, Agnes Y. Y. ;

Conway, Edward M. ;

Wellington, Cheryl L. ;

Sekhon, Mypinder S. .

BLOOD ADVANCES, 2020, 4 (20) :4981-4989

[48] No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study [J].

Huang, Yin-Qiu ;

Tang, Sheng-Quan ;

Xu, Xiao-Lei ;

Zeng, Yan-Ming ;

He, Xiao-Qing ;

Li, Yao ;

Harypursat, Vijay ;

Lu, Yan-Qiu ;

Wan, Yan ;

Zhang, Lu ;

Sun, Qiang-Zhong ;

Sun, Nan-Nan ;

Wang, Gui-Xue ;

Yang, Zhong-Ping ;

Chen, Yao-Kai .

FRONTIERS IN PHARMACOLOGY, 2020, 11

[49] Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial [J].

Jagannathan, Prasanna ;

Andrews, Jason R. ;

Bonilla, Hector ;

Hedlin, Haley ;

Jacobson, Karen B. ;

Balasubramanian, Vidhya ;

Purington, Natasha ;

Kamble, Savita ;

de Vries, Christiaan R. ;

Quintero, Orlando ;

Feng, Kent ;

Ley, Catherine ;

Winslow, Dean ;

Newberry, Jennifer ;

Edwards, Karlie ;

Hislop, Colin ;

Choong, Ingrid ;

Maldonado, Yvonne ;

Glenn, Jeffrey ;

Bhatt, Ami ;

Blish, Catherine ;

Wang, Taia ;

Khosla, Chaitan ;

Pinsky, Benjamin A. ;

Desai, Manisha ;

Parsonnet, Julie ;

Singh, Upinder .

NATURE COMMUNICATIONS, 2021, 12 (01)

[50]

Jones R, 2020, LANCET HIV, V7, pE383, DOI 10.1016/S2352-3018(20)30139-9

← 1 2 3 4 5 6 7 8 9 10 →